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Somestudies suggest that transfusion may be associated withan increased riskofrecurrence of
and death due to malignant human neoplasms. We examined retrospective data from patients
with cervical cancer to see if any association between transfusion of blood at the time of initial
treatment and the time interval to recurrence and death could be detected in this cancer. In 130
patients with cervical cancer, seen over a ten-year period at our institution, there was a trend
toward earlier recurrence in transfused patients, but this trend did not achieve statistical
significance. Death due tocervical cancer recurrence occurred after a median of 12 monthsin the
transfused patients and a median of 68 months in the non-transfused individuals, which was
statistically significant. Transfused patients had, on average, more favorable prognostic factors
than those not transfused, such as less advanced clinical stage of disease. Analysis using a
proportional hazards risk model failed to demonstrate a significant association between transfu-
sion and time to recurrence when other prognostic factors were considered, but a significant
association between transfusion and time to cancer-related death (p < 0.05) was found. While
these results cannot be viewed as conclusive due to the small number and heterogeneity of the
patients analyzed, our data support the possibility of an association between transfusion and
cervical cancer survival. Further studies arewarranted to confirm or refute this relationship.
INTRODUCTION
An extensive body ofdata demonstrates that blood transfusions have immunological
effects on patients and experimental animals, and that these effects may have clinical
consequences [1-3]. The most thoroughly characterized clinical consequence is thatof
improved renal allograft survival in transfused patients, as compared with those not
receiving blood transfusions. These findings have led to investigations of whether
transfusion at the time ofcancer surgery is correlated with immunologic alterations in
patients and with increased rates of tumor recurrence. The first study in humans
demonstrating this relationship is that of Burrows and Tartter on patients with colon
cancer [4]. Numerous studies documenting associations between perioperative trans-
fusion and poorer outcome in patients with colon and rectal [5-6], lung [7-8], breast
[9], and renal [10] cancers as well as soft-tissue sarcomas [11] have appeared. Other
investigators have not found such associations, or have found small differences that do
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not achieve statistical significance [12-18]. One recent study demonstrated an adverse
association between transfusion and colorectal cancer outcome, but no such relation-
ship for breast cancer [19]. The possibility ofsuch a relationship in cervical cancer has
not yet been investigated.
We performed a retrospective case review to determine whether there are associa-
tions between cervical cancer recurrence and survival, and transfusion at the time of
initial diagnosis and treatment.
PATIENTS AND METHODS
The methods employed to collect data on patients with cervical cancer were identical
to those reported in our retrospective study ofcolon and rectal tumors [5]. In brief, the
names and identifying numbers of hospital patients seen between 1970-80 with this
diagnosis were retrieved from a computerized data base and the medical record
reviewed, collecting data on age, date and duration of surgery, transfusion status,
clinical stage, hematocrit at diagnosis, whether radiation therapy or chemotherapy was
received for cervical cancer, recurrence and death data, and last date of follow-up.
Transfusion data were also verified from blood bank records, including whether red
cell transfusions were given as "packed" red cells or as whole blood (whole blood units
contain approximately 300 ml of plasma and anticoagulant; red blood cells, approxi-
mately 50 ml). The attending physician's staging assessment was accepted unless data
to the contrary existed. Clinical stage was defined in our institution according to the
American Joint Committee system, as follows: 0 is carcinoma in situ; IA is microinva-
sive carcinoma;IB is carcinoma restricted to the cervix;IIA is carcinoma extending to
the lateral wall; IIB is carcinoma extending into the vagina; IIIA is carcinoma
penetrating the lateral wall; and IIIB is carcinoma extending to the introitus. Patients
were included in the study if they had undergone surgery at our institution, had
documented follow-up of at least six months, had no evidence of metastatic disease at
diagnosis, and had an unambiguous transfusion history and diagnosis of cancer. We
designated patients as transfused if the transfusions occurred within one month before
or after surgery. Patients receiving transfusions at other times are not included in this
analysis. All transfusions in fact occurred within a several-day span perioperatively.
We excluded 78 patients from the study for the following reasons: 25 had less than six
months' follow-up; 11 had stage IV disease (distant metastases) at presentation; 34
had their initial surgery at another institution; four had missing medical records; three
had more than one malignancy, and one refused any therapy. The remaining 130
patients were included in the analysis.
STATISTICAL ANALYSIS
The methods detailed in our previous study on colon and rectal cancer were
employed [5]. We used chi-square statistics to compare the transfused and non-
transfused groups with respect to the various prognostic factors [20]. We also used
such statistics to compare the incidence of recurrence or death in the various groups
defined by the variables under study. These latter analyses were followed by statistical
techniques which allow adjustment for differences in prognostic factors. A multi-
variate stepwise logistic regression analysis [21] showed that pre-operative anemia,
younger age, less advanced clinical stage, and more prolonged surgery were associated
with transfusion. When fitting proportional hazards models to time to recurrence and
to survival time, we first included the prognostic factors, but not the transfusion status,
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FIG. 1. Kaplan-Meier plot of survival time according to transfusion status. There were 69 transfused
patients and 61 non-transfused patients. Thesedata include only deaths due tocervical cancer, although the
results are similar when deaths due to all causes are included. The two curves are significantly different
(p < 0.05).
as predictors [22]. The non-significant factors were excluded; transfusion status was
then added to the proportional hazards model obtained to see if the change in the log
likelihood after adding transfusion status was significant. By entering information on
transfusion last, we could measure the effect ofblood transfusion on time to recurrence
and survival time after adjustment for other factors. We thus obtained an estimate
ofthe effect on recurrence and on death attributable to blood transfusion status.
Kaplan-Meier's product-limit method was used to estimate the distributions oftime to
recurrence and survival time oftransfused and non-transfused patients [23].
RESULTS
There were no significant differences in the raw frequency ofrecurrence or death in
the transfused (26 percent had recurrences; 16 percent died of cancer) and non-
transfused (30 percent had recurrences; 9 percent died of cancer) groups. When
Kaplan-Meier's product-limit method was employed, however, the survival rate ofthe
transfused patients was worse compared with that ofthe non-transfused patients (Fig.
1). A similar trend was seen in the analysis of time to recurrence, but this difference
was not statistically significant (data not shown).
The patients in the transfused and non-transfused groups were markedly different
from each other in a number ofvariables that are potentially relevant to the likelihood
of cancer recurrence. The transfused group had been followed for a median of 30
months after diagnosis and initial treatment, whereas the non-transfused patients had
been followed for 46 months (p < 0.01 by Mann-Whitney test). Thus the comparable
raw recurrence rates in the transfused and non-transfused groups may be misleading.
Non-transfused patients were followed for 50 percent longer on the median than were
transfused patients and thus are morelikely to have had recurrences detected. Tables 1
and 2 demonstrate that the transfused and non-transfused patients were significantly
different with regard to age, anemia at the time of diagnosis, duration of surgery,
clinical stage, whether radiation therapy was received, and year ofdiagnosis. Ofthese,
age and duration ofsurgery were not significantly associated with recurrence or death;
however, anemia at the time ofdiagnosis, advanced clinical stage, receipt of radiation
therapy, and surgery prior to 1975 were all associated with higher rates ofrecurrence.
Transfused patients were more likely to be anemic at diagnosis, an unfavorable
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TABLE 1
Other Prognostic Variables versus Transfusion Status
Non-Transfused (%) Transfused (%) p
Age <50 years 15/61 (25) 47/69 (68) <0.0001
Hematocrit <38 14/59 (24) 34/67 (51) <0.005
Surgical duration 44/59 (75) 13/66 (20) <0.0001
<120 minutes
Radiation therapy 50/61 (82) 38/68 (56) <0.005
given
Year ofdiagnosis 26/61 (43) 15/69 (22) <0.05
prior to 1975
Chi-square for 2 x 2 tables was employed to determinep values. The choice of intervals for variables
such as age, surgical duration, and year ofdiagnosis was determined by contingency table analysis ofthe
association between these factors and cancer recurrence. Information was not availableon all patients for
all prognostic factors. Age and surgical duration were not prognostically significant factors for recurrence
or death due to cancer. Anemia, receipt of radiotherapy, and diagnosis prior to 1975 were significantly
associated with earlier recurrence and death due to cancer.
prognostic feature. Contrarily, transfused patients were less likely to have stage IIIB
disease, less likely to have received radiation therapy, and less likely to have been
diagnosed prior to 1975, all of which are favorable prognostic associations for the
transfused patients. In general, transfused patients had more favorable clinical
prognostic settings then did those who were not transfused.
A proportional hazard model was fitted to time to recurrence, the results indicating
that pre-operative anemia and presence ofstage IIIB disease were the most significant
factors inpredicting timetorecurrence. Addingtransfusion status tothis model did not
yield a statistically significant improvement in the log-likelihood ratio. When a similar
approach was applied to survival time, however, transfusion was significantly asso-
ciated with shortened survival (p < 0.05).
Thetransfused patients tended ingeneral to have morefavorable prognostic features
and had been followed for a much shorter time. Nonetheless, the raw data on time to
recurrence and survival time show a trend toward earlier recurrence (Fig. 2) and
shorter survival time (Fig. 3) in the transfused patients. Among those with recurrence,
the median time to recurrence for transfused patients was nine months, as compared
TABLE 2
Clinical Stage and Transfusion Status versus Outcome
Died Recurred
Stagea (%) Transfused Non-Transfused Transfused Non-Transfused
0 (20) 0/1 1/4 0/1 2/4
IA (44) 0/7 0/9 0/7 1/9
IB (69) 4/35 1/16 6/35 5/16
IIA (40) 2/4 0/6 2/4 1/6
IIB (50) 3/13 3/13 5/13 3/13
IIIA (50) 0/1 0/1 0/1 0/1
IIIB (40) 2/8 0/12 5/8 6/12
'Percentage refers to the percentage ofpatients with that clinical stage who were transfused.
Chi-square for the distribution ofstages between transfused and non-transfused groups = 9.87,p = 0.13.
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FIG. 2. For the patients with recurrence, months from diagnosis to detection of recurrence are shown
according to transfusion status. Several patients with recurrence are omitted because the exact date
recurrence was detected is not known. The open circle indicates a patient whose recurrence was detected at
192 weeks.
with 24 months for non-transfused patients. Of those dying of cervical cancer, the
median survival time for transfused patients was 12 months, versus 68 months for the
non-transfused patients. These results are statistically significant at thep < 0.05 level
only for survival time.
A recent study which included some ofthe patients in this report demonstrated that
recurrence of cancers of the colon, rectum, prostate, and cervix was more likely in
patients receiving transfusions ofwhole blood than in those receiving red cells [24]. An
analysis ofthe cervical cancer patients alone was performed to determine ifrecurrence
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FIG. 3. For the patients dying ofcervical cancer, months from diagnosis to death are shown according to
transfusion status. The open circle indicates a patient dying ofcervical cancer at 144 weeks.
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was more likely to be associated with transfusions of whole blood, as opposed to red
blood cell concentrates. The association ofrecurrence with amount ofblood transfused
was also investigated. For seven of the transfused patients, the kinds and/or exact
amounts of blood received were unavailable or uncertain. Using chi-square analysis, a
significant association between amount and kind of blood components administered
and recurrence was found. The recurrence rate for those receiving <3 red blood cell
transfusions was 2 of 20, significantly different from 3 of 3 for those receiving .4 red
blood cell transfusions (p = 0.006 by Fisher's exact test). The recurrence rate for those
receiving <3 units of whole blood was 3 of 13, not significantly different from 8 of 26
for those receiving 24 units ofwhole blood. Thus, although the numbers evaluated are
very small, those receiving any whole blood or 24 units of red cells had a greater
frequency ofcancer recurrence.
DISCUSSION
Despite the striking heterogeneity ofthe patients, our data suggest the possibility of
a relationship between death from cervical cancer and transfusion at the time ofinitial
surgical treatment. The patients in the transfused and non-transfused groups are
clearly dissimilar in a number of potentially important respects, but the biases are
toward worse prognostic factors in the non-transfused group. Thus the population
studied is potentially biased against the detection of an adverse effect of transfusion.
Nonetheless, an independentunfavorable association was found between transfusion at
the time ofdiagnosis and death due to cervical cancer.
Counter to what one might expect, the transfused patients had somewhat less
advanced clinical stage disease then did those who were not transfused. The raw
frequencies of recurrence were similar in the transfused and non-transfused patients
despite the fact that thetransfused patients had been followed for much shorter periods
of time. Although multifactorial statistical analysis only demonstrated a significant
association between transfusion and survival time, examination of the raw data for
time to recurrence showed a possible advantage to the non-transfused patients. This
finding is ofinterest as the non-transfused patients had less favorable clinical features:
they were more likely to have been diagnosed prior to 1975, to have received radiation
therapy, and to have more advanced clinical stage ofdisease. Our data also confirmed
that patients receiving plasma-rich products, i.e., whole blood in any amount, or >4
units of red blood cells, had higher recurrence and death rates as compared to those
patients receiving only small numbers of red blood cell transfusions (<3 units).
Because of the small number of patients who died and the heterogeneity of those
studied, our overall analysis of the significance of transfusion in cervical cancer
outcomes is not definitive and will require further study.
In general, our data on cervical cancer tend to support the possibility of an
association between cancer recurrence and transfusion seen in somepatients with other
solid tumors [4-7,9-1 1]. It remains to be determined whether this association is causal
or coincidental. If the relationship is causal, the mechanisms at work are as yet
unknown. Many previous workers have attributed the immunomodulatory effects of
transfusion to the lymphocyte or white cell content of the blood infused. We have
reason to believe that the red cell and whole blood transfusions to our patients did not
differ in lymphocyte or white cell content. Thus, our previous finding [24] that whole
blood transfusions are associated with higher cancer recurrence rates than red blood
cell transfusions suggests a role for plasma substances [25-27] as one potential cause of
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reduced immunologic function in transfused cancer patients. Further studies in patients
might include investigation of the effects of plasma transfusions, unmodified red cell
transfusions, and white cell and plasma-depleted red cell transfusions on immunologic
functions such as natural killer cell activity, antigen presentation function of macro-
phages, and the like, as well as on clinical outcomes.
Whether transfusion causes increased rates of cancer recurrence is still an open
question. Our previous data do argue for the use of red blood cells, rather than whole
blood, when transfusing patients with solid tumors. Nonetheless, the results reported
here are preliminary and tentative when taken alone and cannotjustify changes in the
approach to transfusing cervical cancer patients at this time. Our results do argue in
favor of further study of the relationship between transfusion and cervical cancer
recurrence, and suggest a possible prognostic role for transfusion in this cancer. We
believe that our data in general [5,24-26] strongly support the need for investigations
of the potential benefits of white cell- and plasma-depleted transfusions for cancer
patients requiring red blood cell replacement.
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